U.S. Food and Drug Administration approval summary: Atezolizumab for metastatic non–small cell lung cancer

Clinical Cancer Research

Volumn 23, Issue 16, 2017, Pages 4534-4539

  Weinstock, Chana ^a   Khozin, Sean ^a   Suzman, Daniel ^a   Zhang, Lijun ^a   Tang, Shenghui ^a   Wahby, Sakar ^a   Goldberg, Kirsten B ^a   Kim, Geoffrey ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATEZOLIZUMAB; DOCETAXEL; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ANEMIA; ARTHRALGIA; ARTICLE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLITIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DYSPHAGIA; DYSPNEA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEPATITIS; HUMAN; HYPONATREMIA; HYPOXIA; INTESTINE PERFORATION; LUNG EMBOLISM; METASTATIC NON SMALL CELL LUNG CANCER; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOME; PEPTIC ULCER BLEEDING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID DISEASE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM; ADULT; AGED; CHEMICALLY INDUCED; FEMALE; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; DYSPNEA; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85028073101     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0540     Document Type: Article

References (10)

1. Surveillance, Epidemiology, and End Results Program, National Cancer Institute, Cancer Statistics 2016. Available from: http://seer.cancer.gov/statfacts/html/lungb.html.
2. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926–36.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92–8.
4. Tan C-S, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 2015;16: e447–59.
5. Khozin S, Blumenthal GM, Jiang X, He K, Boyd K, Murgo A, et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 2014;19: 774–9.
6. U.S. Food and Drug Administration. OPDIVO (nivolumab) Prescribing Information, U.S. Food and Drug Administration, 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s031lbl.pdf.
7. U.S. Food and Drug Administration. KEYRTUDA (pembrolizumab) Prescribing Information, U.S. Food and Drug Administration, 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf.
8. U.S. Food and Drug Administration. TECENTRIQ (atezolizumab) Prescribing Information, U.S. Food and Drug Administration, 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761041s000lbl.pdf.
9. Hirsch F, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12:208–22.
10. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre, rando-mised controlled trial. Lancet 2017;389:255–6.